We are focused on the development and commercialization of innovative therapeutics for the treatment of cancer.
Preclinical | Clinical | Marketed | |||||
Indication | Proof of Principle | Safety | Dose Optimization | Clinical Activity | Pivotal | Commercial | |
---|---|---|---|---|---|---|---|
Heme Malignancies | |||||||
Emavusertib* IRAK4 |
IRAK4-driven Leukemia (AML/MDS) | TakeAim Leukemia1 | |||||
Emavusertib* IRAK4 |
IRAK4-driven Lymphoma (NHL, CLL, WM) | TakeAim Lymphoma | |||||
Fimepinostat HDAC/PI3K |
MYC-altered Cancers | ||||||
Immune Checkpoint Inhibitors | |||||||
CI-8993** VISTA |
VISTA-expressing Cancers | ||||||
CA-327* TIM3/PDL1 |
PDL1/TIM3-expressing Cancers | ||||||
CA-170* VISTA/PDL1 |
PDL1/VISTA-expressing Cancers | ||||||
Approved Drug | |||||||
Erivedge*** Hedgehog |
Basal Cell Carcinoma |
Drug | Indication | Stage |
Heme Malignancies | Emavusertib* IRAK4 |
IRAK4-driven Leukemia (AML/MDS) | Clinical Activity |
Emavusertib* IRAK4 |
IRAK4-driven Lymphoma (NHL, CLL, WM) | Clinical Activity |
Fimepinostat HDAC/PI3K |
MYC-altered Cancers | Clinical Activity |
Immune Checkpoint Inhibitors | CI-8993** VISTA |
VISTA-expressing Cancers | Safety |
CA-327* TIM3/PDL1 |
PDL1/TIM3-expressing Cancers | Proof of Principle |
CA-170* VISTA/PDL1 |
PDL1/VISTA-expressing Cancers | Clinical Activity |
Approved Drug | Erivedge*** Hedgehog |
Basal Cell Carcinoma | Commercial |
* IP licensed from Aurigene
** Exclusive option to license IP from ImmuNext
*** IP licensed to Genentech (Curis receives royalty income)
1) In April 2022, the U.S. Food and Drug Administration (“FDA”) placed the TakeAim Leukemia study on partial clinical hold. In August 2022, the FDA notified Curis that it may resume enrollment in the monotherapy dose finding phase of the study. The partial hold remains in place for the combination therapy and expansion phases of the study.